Sienna Biopharmaceuticals Inc. of Westlake Village on Friday announced that it has completed a Series A financing that raised $34 million. Sienna’s lead product is called Silver Plasmonic Therapy, which can be used for acne treatment and permanent hair removal. Silver Plasmonic is currently in the clinical-trial phase. The company’s team includes senior management from Westlake Village-based Kythera Biopharmaceuticals Inc., which was recently acquired by drug giant Allergan of Dublin. “With this proven team and financing, we have a strong foundation from which we can advance our SPT technology and further our efforts in building a pipeline of early to late-stage novel assets,” Sienna’s chief executive, Dr. Frederick C. Beddingfield III, said in a statement. “All the pieces are in place to create the next great company in aesthetics and medical dermatology.” The financing was led by Arch Venture Partners of Chicago and included Altitude Life Science Ventures of Seattle, Partner Fund Management of San Francisco and Venvest Capital of Santa Monica along with other direct investors.
